Nuclear Medicine and Biology
Volume 33, Issue 8 , Pages 1005-1011, November 2006

The tyrosine kinase inhibitor PD153035: implication of labeling position on radiometabolites formed in vitro

  • Erik Samén

      Affiliations

    • Karolinska Pharmacy, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden
  • ,
  • Jan-Olov Thorell

      Affiliations

    • Karolinska Pharmacy, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden
  • ,
  • Anna Fredriksson

      Affiliations

    • Karolinska Pharmacy, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden
  • ,
  • Sharon Stone-Elander

      Affiliations

    • Karolinska Pharmacy, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden
    • Department Clinical Neurosciences, Karolinska Institutet, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden
    • Corresponding Author InformationCorresponding author. Karolinska Pharmacy, Karolinska University Hospital Solna, SE-17176 Stockholm, Sweden. Tel.: +46 8 51775331; fax: +46 8 307346.

Received 7 September 2006; accepted 28 September 2006.

Abstract 

Introduction

The epidermal growth factor receptor is highly expressed in several types of cancers. Molecules with high affinity to its intracellular tyrosine kinase domain are being developed as in vivo imaging probes. The 4-anilinoquinazoline PD153035 has promising in vitro and in vivo properties for development as a reversible radioligand. Labeling it with carbon-11 in either of its two methoxy positions can potentially give rise to different radiometabolites and, consequently, different imaging capabilities. An evaluation of the radiotracers' metabolism was needed to determine the potential significance of the labeling position.

Methods

PD153035 was labeled in the 6- and 7-O-methoxy positions by reacting the corresponding O-desmethyl precursors with [11C]methyl iodide. The two radiolabeled compounds were each incubated for 1 h with human and rat liver microsomes. At five time points, the radiolabeled metabolites were examined using radio-liquid chromatography. One metabolite was isolated and subjected to mass spectroscopic analysis.

Results

A major polar metabolite was obtained in all incubations. Its molecular weight was consistent with an addition of oxygen, and its fragmentation was consistent with an N-oxidation rather than an aromatic hydroxylation. Regioselective 7-O-dealkylation was also observed, albeit in substantial amounts only in the assay using human microsomes.

Conclusions

Radiolabeling in the 7-O-methoxy position is advocated, since the labeled metabolites produced in the 7-O-demethylation are polar and probably rapidly cleared. The differences observed in the incubations with rat and human microsomes suggest that in vivo positron emission tomography studies with 11C-labeled PD153035 in rodents may not be directly predictive for studies in humans.

Keywords: Epidermal growth factor receptor, Tyrosine kinase inhibitor, In vitro metabolism, PD153035, Anilinoquinazoline, Positron emission tomography

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0969-8051(06)00195-8

doi:10.1016/j.nucmedbio.2006.09.008

Nuclear Medicine and Biology
Volume 33, Issue 8 , Pages 1005-1011, November 2006